Symbols

SLXN

Silexion·NASDAQ

--(--)

SLXN Profile

Silexion Therapeutics Corp

A clinical stage biotechnology company specializing in oncology

Industry

Biological Technology

Established Date

Listing Date

04/07/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.silexion.com

Security Type

Common stock

Office address

12 Abba Hillel Road, Ramat-Gan, Israel 5250606

Business

Introduction

Silexion Therapeutics Corp is a Cayman Islands exempted company. The Company is a clinical-stage, oncology-focused biotechnology company developing proprietary therapies for KRAS mutation-driven cancers. Its lead drug candidate, SIL204, is a second-generation small interfering RNA designed to inhibit production of the mutant KRAS protein, initially targeting locally advanced pancreatic cancer.